# BPC-157 Research — Mechanism and Key Findings

> Detailed summary of the BPC-157 research literature: VEGFR2, Akt-eNOS, tissue-repair studies across musculoskeletal, gastrointestinal, neurological, and cardiovascular models. For research purposes only.

## Mechanism of Action

BPC-157 is a 15-amino-acid peptide (GEPPPGKPADDAGLV, MW 1419.5 Da) derived from a protein fraction in human gastric juice. Its mechanistic signature across dozens of rodent studies can be organized around four primary signaling nodes.

**VEGFR2 upregulation.** Vascular endothelial growth factor receptor 2 is a cell-surface kinase that, when activated, drives endothelial cell proliferation and migration. BPC-157 consistently upregulates VEGFR2 expression in healing tissue, and this appears to be the primary upstream event governing its pro-angiogenic activity in tendon and muscle repair models [1][4].

**Akt-eNOS axis activation.** Downstream of VEGFR2, Akt phosphorylates endothelial nitric oxide synthase (eNOS), stimulating nitric oxide production. Nitric oxide drives vasodilation, promotes endothelial survival, and contributes to local angiogenesis. Elevated Akt1 and Nos3 mRNA are among the genes most consistently upregulated — Seiwerth et al. (2021) documented upregulation of both within 10 minutes of BPC-157 application to wound tissue in rats [4].

**ERK1/2 and FAK-paxillin pathway.** Focal Adhesion Kinase (FAK) and its adaptor protein paxillin form a signaling complex that mediates fibroblast adhesion, migration, and proliferation. Chang et al. (2014) demonstrated that at concentrations of 0.1–0.5 μg/mL in isolated rat Achilles tendon fibroblasts, BPC-157 produced up to sevenfold increases in growth hormone receptor mRNA and protein by day three [3].

**NF-kB downregulation and nitric oxide modulation.** BPC-157 reduces NF-kB activity while modulating the nitric oxide system — increasing eNOS-derived NO while decreasing iNOS-derived inflammatory NO [5].

**Tissue-context dependence.** BPC-157's angiogenic behavior is not uniformly pro-angiogenic. In tendon and muscle healing models it promotes neovascularization; in corneal neovascularization models and liver cirrhosis models it opposes pathologic angiogenesis [11].

## Musculoskeletal Findings

**Achilles tendon-to-bone healing.** Krivic et al. (2006): Intraperitoneal administration at 10 μg/kg, 10 ng/kg, and 10 pg/kg consistently produced superior load-to-failure values, stiffness, and Young's modulus compared to controls. Also counteracted methylprednisolone-induced healing impairment [2]. PRECLINICAL.

**Angiogenesis in crushed and transected tissue.** Brcic et al. (2009): Upregulated VEGF expression and more organized angiogenesis at the repair site; no direct angiogenic effect in cell culture — activity required an in vivo healing environment [1]. PRECLINICAL.

**Growth hormone receptor in tendon fibroblasts.** Chang et al. (2014): At 0.1–0.5 μg/mL in isolated rat Achilles tendon fibroblasts — up to sevenfold increases in GH receptor mRNA/protein by day three [3]. IN VITRO.

**Quadriceps muscle-to-bone reattachment.** Matek et al. (2025): Oral BPC-157 at 10 μg/kg or 10 ng/kg. At 90 days, treated animals showed consistent muscle-to-bone reattachment with mature, parallel-oriented collagen fibers. Controls showed permanent contracture [12]. PRECLINICAL.

## Gastrointestinal Findings

**Wound healing across skin and gut.** Seiwerth et al. (2021): Topical, IP, and oral routes across skin incisions, burns, diabetic ulcers, and fistulas. Accelerated re-epithelialization, enhanced angiogenesis, outperformed silver sulfadiazine in burn model. Gene expression upregulation within 10 minutes [4]. PRECLINICAL.

**Fistula closure.** Vukusic et al. (2024): All routes produced complete closure of duodenocolic fistulas, elimination of leakage, prevention of weight loss, and significantly reduced adhesion formation [15]. PRECLINICAL.

**Vascular occlusion and organ protection.** Sikiric et al. (2022): BPC-157 rapidly recruited collateral vessels, reversed hypertension, prevented thrombosis, and attenuated lesions across liver, kidney, GI tract, and heart in four occlusion models [9]. PRECLINICAL.

## Neurological and Cardiovascular Findings

**Hippocampal ischemia-reperfusion.** Vukojevic et al. (2020): Local BPC-157 at 10 μg/kg produced complete functional recovery at 24 and 72 hours. Elevated Egr1, Akt1, Vegfr2, Nos3; decreased Nos2 and NF-kB [5]. PRECLINICAL.

**Spinal cord compression.** Perovic et al. (2019): Single IP injection at 200 μg/kg or 2 μg/kg — progressive motor recovery, resolution of spasticity by day 15, prevention of autotomy through 360 days [6]. PRECLINICAL.

**Dopaminergic system.** Vukojevic et al. (2022): Normalized dopaminergic signaling and reversed haloperidol-induced catalepsy across multiple disturbance models via nitric oxide system modulation [7]. REVIEW.

**Pulmonary arterial hypertension.** Udovicic et al. (2021): At 10 μg/kg or 10 ng/kg, prevented and reversed pulmonary arterial wall thickening and right ventricular hypertrophy. 0% mortality in treated vs 50% in controls [8]. PRECLINICAL.

**Remote organ protection.** Demirtas et al. (2025): Single 20 μg/kg IP dose attenuated renal, pulmonary, and hepatic injury following lower-extremity ischemia-reperfusion [14]. PRECLINICAL.

**Human pilot data.** McGuire et al. (2025): Three published human studies, 28 participants total. Intra-articular knee (14 patients, 87.5% significant pain relief), intravesical for interstitial cystitis (12 patients, 80–100% symptom resolution), IV safety study (2 volunteers, no adverse events). No Phase 2 or Phase 3 RCTs completed [13]. HUMAN PILOT.

## References

[1] Brcic L, et al. J Physiol Pharmacol. 2009. PMID: 20388964.
[2] Krivic A, et al. J Orthop Res. 2006. DOI: 10.1002/jor.20096.
[3] Chang CH, et al. Molecules. 2014. DOI: 10.3390/molecules191119066.
[4] Seiwerth S, et al. Front Pharmacol. 2021. DOI: 10.3389/fphar.2021.627533.
[5] Vukojevic J, et al. Brain Behav. 2020. DOI: 10.1002/brb3.1726.
[6] Perovic D, et al. J Orthop Surg Res. 2019. DOI: 10.1186/s13018-019-1242-6.
[7] Vukojevic J, et al. Neural Regen Res. 2022. DOI: 10.4103/1673-5374.320969.
[8] Udovicic M, et al. Biomedicines. 2021. DOI: 10.3390/biomedicines9070822.
[9] Sikiric P, et al. World J Gastroenterol. 2022. DOI: 10.3748/wjg.v28.i1.23.
[11] Sikiric P, et al. Pharmaceuticals. 2025. DOI: 10.3390/ph18060928.
[12] Matek D, et al. Pharmaceutics. 2025. DOI: 10.3390/pharmaceutics17010119.
[13] McGuire FP, et al. Curr Rev Musculoskelet Med. 2025. DOI: 10.1007/s12178-025-09990-7.
[14] Demirtas H, et al. Medicina. 2025. DOI: 10.3390/medicina61020291.
[15] Vukusic D, et al. J Physiol Pharmacol. 2024. DOI: 10.26402/jpp.2024.1.09.

---

For research purposes only. Not for human consumption. This site does not sell any product and is not affiliated with any vendor.